Weeks after launching its first open call for diabetes advocates, Dexcom is spotlighting the resulting group of 16 people in ...

DexCom's growth rate has been improving, but that hasn't been enough of a reason for investors to buy up the stock.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is ...

Morgan Stanley lowered the firm’s price target on DexCom (DXCM) to $63 from $89 and keeps an Overweight rating on the shares. Published first on ...

Bullish option flow detected in DexCom (DXCM) with 4,618 calls trading, 1.3x expected, and implied vol increasing almost 3 points to 63.76%. Dec-25 85 calls and 10/24 weekly 73 calls are the most ...

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Piper Sandler highlighted that DexCom stock is currently trading at its lowest valuation level in ...

The company’s strong financial health score of "GREAT" on InvestingPro supports this outlook, with robust cash flows and moderate debt levels. TD Cowen expects DexCom’s upcoming third-quarter results ...

DexCom was hit with a consumer class action on Oct. 22 in California Southern District Court over allegations it made unauthorized design changes to its G6 and G7 continuous glucose monitors without ...

Investing.com - BTIG lowered its price target on DexCom (NASDAQ:DXCM) to $85 from $109 on Friday, while maintaining a Buy rating following the company’s third-quarter earnings report. The new target ...

SAN DIEGO - Dexcom, Inc. (NASDAQ:DXCM), a glucose biosensing technology company with a market capitalization of $27.69 billion and an "GREAT" financial health rating according to InvestingPro, ...

San Diego-based Dexcom Inc., is the target of a class action lawsuit in U.S. district court over the company’s G7 continuous glucose monitors, an action which follows a U.S. FDA warning letter by a ...